v3.24.3

Intangible Assets | 3 Months Ended
--- | ---
Sep. 30, 2024
Intangible Assets |
Intangible Assets | 11. Intangible Assets On August 23, 2021, the Company entered into a series of agreements with RubrYc (see Note 6 – Significant Transactions) whereby the Company in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. In addition, the Company also received preferred shares and an option for future collaboration licenses. ​ On September 16, 2022, the Company entered into an asset purchase agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate. ​ The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | September 30, |  | June 30,
​ | ​ | 2024 | ​ | 2024
Intellectual property – gross carrying value | ​ | $ | 400 | ​ | $ | 400
Intellectual property – accumulated amortization | ​ |  | (40) | ​ |  | (35)
Total definite lived intangible assets, net of accumulated amortization | ​ | ​ | 360 | ​ | ​ | 365
​ | ​ | ​ | ​ | ​ | ​ | ​
Intellectual property – indefinite lived | ​ | ​ | 5,003 | ​ | ​ | 5,003
​ | ​ | ​ | ​ | ​ | ​ | ​
Total net intangible assets | ​ | $ | 5,363 | ​ | $ | 5,368
​ Amortization expense was approximately $5,000 for the three month periods ended September 30, 2024 and 2023. ​ See Note 4 - Summary of Significant Accounting Policies and Note 5 – Financial Instruments and Fair Value Measurement for more information.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration